Viewing Study NCT02492321



Ignite Creation Date: 2024-05-06 @ 7:14 AM
Last Modification Date: 2024-10-26 @ 11:46 AM
Study NCT ID: NCT02492321
Status: COMPLETED
Last Update Posted: 2016-02-11
First Post: 2015-07-02

Brief Title: A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis
Sponsor: Eleven Biotherapeutics
Organization: Eleven Biotherapeutics

Study Overview

Official Title: A Multi-Center Randomized Double-Masked Vehicle-Controlled Evaluation of the Efficacy Safety and Tolerability of EBI-005 in Subjects With Moderate to Severe Ocular Allergic Conjunctivitis
Status: COMPLETED
Status Verified Date: 2016-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: EBI-005-AC-2
Brief Summary: This is a Phase III multi-center double-masked vehicle-controlled randomized parallel group study evaluating the efficacy safety and tolerability of EBI-005 as compared to vehicle given as a topical ophthalmic solution in each eye to subjects with moderate to severe allergic conjunctivitis AC three times daily for 4 weeks

Approximately 250 subjects at approximately 8 centers in the US will be screened and enrolled into the study
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None